Alzamend Neuro, Inc. (ALZN)
1.13
+0.01
(+0.89%)
USD |
NASDAQ |
Oct 23, 16:00
1.13
0.00 (0.00%)
After-Hours: 20:00
Alzamend Neuro Shareholders Equity (Quarterly) : 5.803M for July 31, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| July 31, 2026 | 5.803M |
| April 30, 2026 | 0.7332M |
| January 31, 2026 | 2.184M |
| October 31, 2025 | 4.374M |
| July 31, 2025 | 5.343M |
| April 30, 2025 | 3.968M |
| January 31, 2025 | 3.450M |
| October 31, 2024 | 3.753M |
| July 31, 2024 | -1.212M |
| April 30, 2024 | -2.594M |
| January 31, 2024 | -4.194M |
| Date | Value |
|---|---|
| October 31, 2023 | -2.682M |
| July 31, 2023 | -0.1129M |
| April 30, 2023 | 3.046M |
| January 31, 2023 | 5.860M |
| October 31, 2022 | 8.787M |
| July 31, 2022 | 11.18M |
| April 30, 2022 | 13.35M |
| January 31, 2022 | 11.96M |
| October 31, 2021 | 13.03M |
| July 31, 2021 | 15.34M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 8.542M |
| Total Liabilities (Quarterly) | 2.739M |
| Current Ratio | 3.013 |